Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 5 | BMC Immunology

Fig. 5

From: The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer

Fig. 5

The increased Tregs proliferation depressed the level of effector CD8+ T cells after PD-L1 treatment. A The change of Ki67+ Tregs in the peripheral blood of mice after anti-PD-L1 treatment. The blood was collected at the endpoint. N = 4. Two-tailed unpaired T-test was performed. B The mRNA level of Ki67 in sorted Tregs cells from the spleen of mouse. N = 3. Two-tailed unpaired T-test was performed. CE The change of the frequency of effector CD8+ T cells in tumor (C), the peripheral blood (D) and DLN (E) at the endpoint. N = 4. The effector CD8 + T cell was defined as CD3+CD8+CD62LCD44+. Two-tailed unpaired T-test was performed. ns: no significant difference, *p < 0.05, **p < 0.01compared to the control groups. A p value less than 0.05 was considered to be statistically significant

Back to article page